Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1810-1822

  Hosoi, Akihiro ^a,b   Matsushita, Hirokazu ^a   Shimizu, Kanako ^c   Fujii, Shin Ichiro ^c   Ueha, Satoshi ^d   Abe, Jun ^d   Kurachi, Makoto ^d   Maekawa, Ryuji ^b   Matsushima, Kouji ^d   Kakimi, Kazuhiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b University of Tokyo   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

adoptive transfer; CTL; immunotherapy; MDSC

Indexed keywords

ADOPTIVE TRANSFER; CTL; IMMUNOTHERAPY; MDSC;

ANIMALS; ANTIGENS, CD11B; ARGINASE; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; NEOPLASTIC STEM CELLS; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RECEPTORS, CCR2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84893719720     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28506     Document Type: Article

References (39)

1. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev 2008; 8: 299-308. (Pubitemid 351430867)
2. Brenner MK, Heslop HE,. Adoptive T cell therapy of cancer. Curr Opin Immunol 2010; 22: 251-7.
3. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9. (Pubitemid 44547756)
4. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-24.
5. Kohn DB, Dotti G, Brentjens R, et al. CARs on track in the clinic. Mol Ther 2011; 19: 432-8.
6. Jena B, Dotti G, Cooper LJ,. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116: 1035-44.
7. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
8. Sadelain M,. T-cell engineering for cancer immunotherapy. Cancer J 2009; 15: 451-5.
9. Zou W,. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev 2005; 5: 263-74. (Pubitemid 40488632)
10. Rabinovich GA, Gabrilovich D, Sotomayor EM,. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96. (Pubitemid 46697910)
11. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198: 569-80. (Pubitemid 37040391)
12. Noji S, Hosoi A, Takeda K, et al. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy. J Immunother 2012; 35: 460-72.
13. Boring L, Gosling J, Chensue SW, et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100: 2552-61. (Pubitemid 27514895)
14. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92. (Pubitemid 29096240)
15. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78. (Pubitemid 37324571)
16. Eruslanov E, Kusmartsev S,. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 2010; 594: 57-72.
17. Ueha S, Murai M, Yoneyama H, et al. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. J Leukoc Biol 2007; 81: 176-85. (Pubitemid 46021267)
18. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828-35. (Pubitemid 47038194)
19. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-802.
20. Sawanobori Y, Ueha S, Kurachi M, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008; 111: 5457-66.
21. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
22. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-44.
23. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V,. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
24. Talmadge JE,. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007; 13: 5243-8. (Pubitemid 47510346)
25. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
26. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-44.
27. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
28. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116: 2777-90. (Pubitemid 44511641)
29. Huang B, Lei Z, Zhao J, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007; 252: 86-92. (Pubitemid 46734559)
30. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-5.
31. Geissmann F, Jung S, Littman DR,. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82. (Pubitemid 36859902)
32. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-94. (Pubitemid 46048465)
33. Lesokhin AM, Hohl TM, Kitano S, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72: 876-86.
34. Fridlender ZG, Buchlis G, Kapoor V, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010; 70: 109-18.
35. Cheever MA, Greenberg PD, Fefer A,. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 1980; 125: 711-14. (Pubitemid 10005585)
36. North RJ,. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155: 1063-74. (Pubitemid 12142723)
37. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4. (Pubitemid 35231542)
38. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-57. (Pubitemid 46218728)
39. Landsberg J, Kohlmeyer J, Renn M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490: 412-16.